Zealand Pharma A/S
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zealand Pharma A/S
The results could help BI and Zealand Pharma challenge in the MASH field, though analysts are wary of claims around fibrosis improvement.
Target adds more than 1,000 wellness products to its shelves; Whole Foods has exclusive deal with InBlooom; and RxBar makes “ultimate breakup gift” promotion.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Licensing serves as a strategic R&D avenue for major developers amid a shrinking M&A market. In Vivo has detected five high-value unpartnered assets that might be the focus of dealmaking activity in the coming months.
- Other Names / Subsidiaries
- Encycle Therapeutics, Inc.
- Valeritas Holdings, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.